Regulatory opportunities to encourage technology solutions to antibacterial drug resistance

Research output: Contribution to journalArticlepeer-review

Standard

Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. / Finch, Roger; BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development ; Piddock, Laura.

In: Journal of Antimicrobial Chemotherapy, Vol. 66, No. 9, 09.2011, p. 1945-7.

Research output: Contribution to journalArticlepeer-review

Harvard

Finch, R, BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development & Piddock, L 2011, 'Regulatory opportunities to encourage technology solutions to antibacterial drug resistance', Journal of Antimicrobial Chemotherapy, vol. 66, no. 9, pp. 1945-7. https://doi.org/10.1093/jac/dkr259

APA

Finch, R., BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development, & Piddock, L. (2011). Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. Journal of Antimicrobial Chemotherapy, 66(9), 1945-7. https://doi.org/10.1093/jac/dkr259

Vancouver

Finch R, BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development, Piddock L. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. Journal of Antimicrobial Chemotherapy. 2011 Sep;66(9):1945-7. https://doi.org/10.1093/jac/dkr259

Author

Finch, Roger ; BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development ; Piddock, Laura. / Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. In: Journal of Antimicrobial Chemotherapy. 2011 ; Vol. 66, No. 9. pp. 1945-7.

Bibtex

@article{a8354d3d913a45b58ef131a6e3b78610,
title = "Regulatory opportunities to encourage technology solutions to antibacterial drug resistance",
abstract = "Regulatory agencies play a critical role in the licensing of new antimicrobial agents. To address the pivotal role played by regulatory agencies, particularly in the context of a paucity of new drugs active against bacteria resistant to currently available drugs, the BSAC formed the 'Urgent Need' Working Party to address the regeneration of antibacterial drug discovery and development. The Working Party identified a number of issues, including: increased application of pharmacokinetic/pharmacodynamic principles to expedite drug development; the need to prioritize licensing of drugs (including 'orphan' drugs) active in life-threatening infections; and expansion of the use of surrogate markers and rapid point of care diagnostics to facilitate drug development.",
keywords = "Anti-Bacterial Agents, Bacterial Infections, Diffusion of Innovation, Drug Design, Drug Resistance, Bacterial, Humans, Legislation, Drug, Microbiology, Technology",
author = "Roger Finch and {BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development} and Laura Piddock",
year = "2011",
month = sep,
doi = "10.1093/jac/dkr259",
language = "English",
volume = "66",
pages = "1945--7",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Regulatory opportunities to encourage technology solutions to antibacterial drug resistance

AU - Finch, Roger

AU - BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development

AU - Piddock, Laura

PY - 2011/9

Y1 - 2011/9

N2 - Regulatory agencies play a critical role in the licensing of new antimicrobial agents. To address the pivotal role played by regulatory agencies, particularly in the context of a paucity of new drugs active against bacteria resistant to currently available drugs, the BSAC formed the 'Urgent Need' Working Party to address the regeneration of antibacterial drug discovery and development. The Working Party identified a number of issues, including: increased application of pharmacokinetic/pharmacodynamic principles to expedite drug development; the need to prioritize licensing of drugs (including 'orphan' drugs) active in life-threatening infections; and expansion of the use of surrogate markers and rapid point of care diagnostics to facilitate drug development.

AB - Regulatory agencies play a critical role in the licensing of new antimicrobial agents. To address the pivotal role played by regulatory agencies, particularly in the context of a paucity of new drugs active against bacteria resistant to currently available drugs, the BSAC formed the 'Urgent Need' Working Party to address the regeneration of antibacterial drug discovery and development. The Working Party identified a number of issues, including: increased application of pharmacokinetic/pharmacodynamic principles to expedite drug development; the need to prioritize licensing of drugs (including 'orphan' drugs) active in life-threatening infections; and expansion of the use of surrogate markers and rapid point of care diagnostics to facilitate drug development.

KW - Anti-Bacterial Agents

KW - Bacterial Infections

KW - Diffusion of Innovation

KW - Drug Design

KW - Drug Resistance, Bacterial

KW - Humans

KW - Legislation, Drug

KW - Microbiology

KW - Technology

U2 - 10.1093/jac/dkr259

DO - 10.1093/jac/dkr259

M3 - Article

C2 - 21700629

VL - 66

SP - 1945

EP - 1947

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 9

ER -